Consistent with our preclinical data, we discovered that patients with ICI-responsive GBM had significantly lower ZNF638 expression than nonresponders and was associated with a significantly improved overall survival (Figure 9, B and C). This evidence concerns the gene ZNF638 and glioblastoma.